Stock HPHA HEIDELBERG PHARMA AG
Add to a list
To use this feature you must be a member
Log inSign up

News Heidelberg Pharma AG

Equities

HPHA

DE000A11QVV0

Market Closed - Xetra
Other stock markets
 11:36:04 2024-04-19 am EDT 		After market 12:43:24 pm
3 EUR +1.35% Intraday chart for Heidelberg Pharma AG 2.995 -0.17%
Mar. 27 Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment MT
Mar. 25 Transcript : Heidelberg Pharma AG, 2023 Earnings Call, Mar 25, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
DD: Heidelberg Pharma AG: Walter Miller, buy
EQ
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
EQ
PM: Heidelberg Pharma receives Orphan Drug Designation from the FDA for its ATAC candidate HDP-101
AQ
Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment
MT
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
EQ
DD: Heidelberg Pharma AG: Dr. Georg F. Baur, buy
EQ
Heidelberg Pharma : Presentation Analyst and Press Conference 2024
PU
Heidelberg Pharma : Präsentation Bilanzpressekonferenz 2024
PU
Transcript : Heidelberg Pharma AG, 2023 Earnings Call, Mar 25, 2024
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
EQ
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2023
CI
Heidelberg Pharma : Presentation
PU
Heidelberg Pharma Concludes Royalty Purchase Deal with HealthCare Royalty
MT
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
EQ
Heidelberg Pharma : Statement on Corporate Governance 2023 as of 19 March 2024
PU
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
EQ
PM, Heidelberg Pharma Presents Initial Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR 2024 Meeting
AQ
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
EQ
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQ
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HPHA Stock
  4. News Heidelberg Pharma AG